THE NEUROLOGIST, like an Argonaut in his search for the Golden Fleece, has through the years been doggedly trying to achieve his lofty goal of optimally treating his or her patients with multiple sclerosis (MS). Progress has been made. A recombinant cytokine, interferon beta (administered as Betaseron or Avonex), has been widely used in the past decade and is the first recombinant protein extensively prescribed by neurologists. It is thus a "pioneer" therapy from which we all need to learn as much as possible before the next recombinant protein is available.
Pachner AR. Measurement of Antibodies to Interferon Beta in Patients With Multiple Sclerosis. Arch Neurol. 2001;58(8):1299-1300. doi:10.1001/archneur.58.8.1299